Mechanisms and strategies for prevention in diabetic retinopathy

Current Diabetes Reports

Volumn 6, Issue 2, 2006, Pages 102-107

  Lorenzi, Mara ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; BENFOTIAMINE; CANDESARTAN; DIPYRIDAMOLE; HEMOGLOBIN A1C; INSULIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PEGAPTANIB; PYRIDOXAMINE; RUBOXISTAURIN; SORBINIL;

CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; METABOLIC DISORDER; MICROANEURYSM; NONHUMAN; PREVENTIVE MEDICINE; REVIEW; TREATMENT PLANNING; VISUAL IMPAIRMENT;

ANIMALS; CLINICAL TRIALS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 33645772017     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0019-6     Document Type: Review

References (43)

1. Ramsay R, Goetz F, Sutherland D, et al.: Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:208-214.
2. Petersen M, Vine A: Progression of diabetic retinopathy after pancreas transplantation. Ophthalmology 1990, 97:496-502.
3. Kennedy W, Navarro X, Goetz F, et al.: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990, 322:1031-1037.
4. Fioretto P, Steffes M, Sutherland D, et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
5. Early worsening of diabetic retinopathy in the diabetes control and complications trial [no authors listed]. Arch Ophthalmol 1998, 116:874-886.
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [no authors listed]. N Engl J Med 1993, 329:977-986.
7. Engerman R, Kern T: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
8. Roy S, Sala R, Cagliero E, Lorenzi M: Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A 1990, 87:404-408.
9. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effects of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
10. The Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. The epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003, 290:2159-2167.
11. Nathan DM, Lachin J, Cleary P, et al.: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellltus. N Engl J Med 2003, 348:2294-2303.
12. Mizutani M, Kern T, Lorenzi M: Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996, 97:2883-2890.
13. Mecham R, Whitehouse L, Wrenn D, et al.: Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science 1987, 237:423-426.
14. Munsat T: Poliomyelitis - new problems with an old disease. N Engl J Med 1991, 324:1206-1208.
15. Mohsin F, Craig M, Cusumano J, et al.: Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005, 28:1974-1980.
16. Asnaghi V, Gerhardinger C, Hoehn T, et al.: A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003, 52:506-511.
17. Dagher Z, Park YS, Asnaghi V, et al.: Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004, 53:2404-2411.
18. Mizutani M, Gerhardinger C, Lorenzi M: Müller cell changes in human diabetic retinopathy. Diabetes 1998, 47:445-449.
19. Engerman R, Kern T: Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995, 11:109-120.
20. Hammes HP, Lin J, Renner O, et al.: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002, 51:3107-3112.
21. Barber A, Antonetti D, Kern T, et al.: The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005, 46:2210-2218.
22. Gerhardinger C, Cost MB, Coulombe M, et al.: Expression of acute-phase response proteins in retinal Müller cells in diabetes. Invest Ophthalmol Vis Sci 2005, 46:349-357.
23. Stitt A, Gardiner T, Anderson N, et al.: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002, 51:2826-2832.
24. Hammes HP, Du X, Edelstein D, et al.: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
25. Zheng L, Szabo C, Kern T: Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004, 53:2960-2967.
26. Kern TS, Engerman R: Pharmacological inhibition of diabetic retinopathy. Aminoguanidine and aspirin. Diabetes 2001, 50:1636-1642.
27. Sun W, Gerhardinger C, Dagher Z, et al.: Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 2005, 54:3418-3426.
28. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
29. Sochor M, Kunjara S, McLean P: The effect of aldose reductase inhibitor Statil (ICI 128436) on the glucose over-utilization in kidney of diabetic rats. Biochem Pharmacol 1988, 37:3349-3356.
30. Cheng HM, Hirose K, Xiong H, Gonzalez R: Polyol pathway activity in streptozotocin-diabetic rat lens. Exp Eye Res 1989, 49:87-92.
31. Wu G, Marliss EB: Enhanced glucose metabolism and respiratory burst in peritoneal macrophages from spontaneously diabetic BB rats. Diabetes 1993, 42:520-529.
32. Chung SSM, Chung SK: Aldose reductase in diabetic microvascular complications. Curr Drug Targets 2005, 6:475-486.
33. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group [no authors listed]. Arch Ophthalmol 1990, 108:1234-1244.
34. Pillinger M, Capodici C, Rosenthal P. et al.: Modes of action of aspirin-like drugs: salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A 1998, 95:14540-14545.
35. Mylari BL, Armento SJ, Beebe DA, et al.: A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3-one. J Med Chem 2003, 46:2283-2286.
36. Hotta N, Toyota T, Matsuoka K, et al.: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001, 24:1776-1782.
37. Bril V, Buchanan RA: Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004, 27:2369-2375.
38. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group [no authors listed]. Ophthalmology 1991, 98:757-765.
39. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group [no authors listedl. Diabetes 1989, 38:491-498.
40. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. The PKC-DRS Study Group [no authors listed]. Diabetes 2005, 54:2188-2197.
41. Wilkinson-Berka JL: Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2005, Sep 12;
42. Charbonnel B, Massin P: The Diabetic Retinopathy Candesartan Trials (DIRECT): rationale and design [abstract]. J Hypertens 2005, 23:A5.
43. Cunningham ET Jr, Adamis AP, Altaweel M, et al.: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112:1747-1757.